ARTES Biotechnology and Midas Pharma signed Cooperation Contract
(PresseBox) - ARTES Biotechnology announced the collaboration with Midas Pharma for strategic marketing opportunities. Aim of the cooperation is the finding of suitable partners for defined pharmaceuticals projects like vaccine and pharmaceutical target development or transfer of Biosimilar processes.
ARTES is specialized in microbial cell line and process development as well as in technology transfer for pharmaceutical industry whereas Midas is an independent marketing and distribution company, which supports clients in finding potential partners and markets.
?We are confident, that we could, together with Midas? worldwide representatives, break into new markets. Especially our vaccine development platform Metavax® has strong capabilities. The Metavax® platform is suitable for the development and production of cost-effective vaccines and therefore interesting for markets where price is an issue?, Dr. Melanie Piontek, Business Development Director of ARTES pointed out. ?The highly expanded network of Midas will open for us new opportunities currently in regions where we not yet in. We are very pleased that, with Midas, we have been able to acquire a very competent and reliable partner.?
ARTES is a Germany-based biotechnology company specialized in recombinant protein production and process development from microbial expression systems. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld. The company focuses on contract R&D for red and white biotechnology products.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
ARTES is a Germany-based biotechnology company specialized in recombinant protein production and process development from microbial expression systems. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld. The company focuses on contract R&D for red and white biotechnology products.
Datum: 24.06.2013 - 04:34 Uhr
Sprache: Deutsch
News-ID 1239383
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Langenfeld
Phone:
Kategorie:
Handcrafts
Anmerkungen:
Diese Pressemitteilung wurde bisher 302 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ARTES Biotechnology and Midas Pharma signed Cooperation Contract
"
steht unter der journalistisch-redaktionellen Verantwortung von
ARTES Biotechnology GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
